Form 4: TriSalus Life Sciences Executive Receives Stock Grant
SEC Form 4 Filing
Bryan F. Cox, Chief of Research at TriSalus Life Sciences, reports the acquisition of 11,450 shares of common stock through a restricted stock unit (RSU) award.
Summary
- Bryan F. Cox, the Chief of Research at TriSalus Life Sciences, acquired 11,450 shares of common stock on February 18, 2025, through a restricted stock unit (RSU) award.
- The shares were acquired at a price of $0.
- Following the transaction, Cox directly owns 108,457 shares of TriSalus Life Sciences.
- The RSU award vests in installments: 12.5% on the grant date (February 18, 2025), 25% on May 15, 2025, August 15, 2025, and November 14, 2025, and the remaining shares on February 13, 2026, contingent upon continued service with the Issuer.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The grant of RSUs to a key executive is generally a positive sign, indicating confidence in the company's future. However, it's a routine transaction and doesn't provide significant new information about the company's performance.
Positives
- The grant of RSUs to a key executive like the Chief of Research suggests an alignment of interests between management and shareholders.
- The vesting schedule incentivizes continued service and commitment from the executive.
Future Outlook
The document does not contain specific forward-looking statements about the company's overall performance, but the vesting schedule of the RSU award suggests an expectation of continued service and contribution from the executive.
Industry Context
Stock grants are a common practice in the life sciences industry to attract and retain talent, aligning their interests with the long-term success of the company.
Stakeholder Impact
- Shareholders may view the RSU grant as a positive sign, aligning management's interests with the company's long-term success.
- Employees may see this as a positive sign of investment in key personnel.
Key Dates
| Date | Description |
|---|---|
| 02/18/2025 | Date of the transaction (grant of restricted stock units) |
| 02/18/2025 | 12.5% of the shares subject to the RSU Award shall vest |
| 05/15/2025 | 25% of the shares subject to the RSU Award shall vest |
| 08/15/2025 | 25% of the shares subject to the RSU Award shall vest |
| 11/14/2025 | 25% of the shares subject to the RSU Award shall vest |
| 02/13/2026 | Remaining shares subject to the RSU Award will vest |
| 02/19/2025 | Date of signature |
Keywords
TriSalus Life Sciences, TLSI, Bryan F. Cox, restricted stock units, RSU, beneficial ownership, Form 4, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.